RxDoctor Payments Data

Fred Itveldt

Psychiatric/Mental Health · Spokane Valley, WANPI 1619393204

Payments from drug & device makers

$2,706in general payments, 2019–2025

Across 78 payments — averaging $34.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$732
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$384
  • Teva Pharmaceuticals USA, Inc.$268
  • AbbVie$239
  • Otsuka America Pharmaceutical, Inc.$182
  • E.r. Squibb & Sons, L.L.C.$163
  • plus $737 from 10 others

What the payments were for

  • Consulting fees$1154%
  • Food & beverage$2,47291%
  • Education$1184%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,706 in reported general payments places this provider in the 85th percentile of 931 psychiatric/mental health providers in Washington.

See all psychiatric/mental health providers in Washington

Medicare billing

Part B allowed, 2024
$9,995
Medicare patients
26
Services billed
139

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl136$174,650
VraylarCariprazine Hcl39$53,828
FanaptIloperidone13$38,929
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl57$11,330
Aripiprazole43$5,541
Olanzapine50$3,981
Buprenorphine14$3,126
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine35$2,139
Duloxetine Hcl41$1,185
Escitalopram Oxalate39$1,171
Doxepin Hcl35$1,148
Quetiapine Fumarate64$1,064
Prazosin Hcl39$975
Dexmethylphenidate Hcl24$930
Bupropion XlBupropion Hcl24$777

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$732$174,650136 claims
AbbVieVraylar$239$53,82839 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 931 psychiatric/mental health providers in Washington.

Other psychiatric/mental health in Spokane Valley

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →